A Lesson from a Measles Outbreak among Healthcare Workers in a Single Hospital in South Korea: The Importance of Knowing the Prevalence of Susceptibility.
HCWs
immunity
measles
outbreak
vaccination
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
20 Sep 2023
20 Sep 2023
Historique:
received:
24
07
2023
revised:
05
09
2023
accepted:
08
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Despite the high vaccination coverage rate, in-hospital transmission of measles continues to occur in South Korea. We present a measles outbreak in which two healthcare workers (HCWs) with presumptive evidence of measles immunity were infected by a patient with typical measles at a single hospital in South Korea. This facilitated the evaluation of measles seroprevalence in all HCWs. In 2018, suspected patients and contacts exposed during a measles outbreak were investigated based on their medical histories and vaccination status. Cases were confirmed by the detection of measles-specific immunoglobulin M or RNA. After the measles outbreak in 2018, measles IgG testing was conducted on a total of 972 HCWs for point-prevalence, including those exposed to the measles. In addition, we have routinely performed measles IgG tests on newly employed HCWs within one week of their hire date since 2019. The measles vaccine was administered to HCWs who tested negative or equivocally negative for IgG antibodies. An index patient who returned from China with fever and rash was diagnosed with measles at a hospital in Korea. Two additional HCWs were revealed as measles cases: one was vaccinated with the two-dose measles-mumps-rubella (MMR) vaccine, and the other, who was born in 1967, was presumed to have immunity from natural infection in South Korea. All three patients harbored the same D8 genotype. No additional measles cases were identified among the 964 contacts of secondary patients. A total of 2310 HCWs, including those tested during the 2018 outbreak, underwent measles IgG tests. The average age at the time of the test was 32.6 years, and 74.3% were female. The overall seropositivity of measles was 88.9% (95% confidence interval, 87.5-90.1). Although the birth cohorts between 1985 and 1994 were presumed to have received the measles-rubella (MR) catch-up vaccination in 2001, 175 (89.3%) HCWs were born after 1985 among the 195 seronegative cases. Despite high population immunity, imported measles transmission occurred among HCWs with presumed immunity. This report underscores the importance of understanding the prevalence of measles susceptibility among newly employed HCWs. This is important for policymaking regarding hospital-wide vaccinations to prevent the spread of vaccine-preventable diseases.
Sections du résumé
BACKGROUND
BACKGROUND
Despite the high vaccination coverage rate, in-hospital transmission of measles continues to occur in South Korea. We present a measles outbreak in which two healthcare workers (HCWs) with presumptive evidence of measles immunity were infected by a patient with typical measles at a single hospital in South Korea. This facilitated the evaluation of measles seroprevalence in all HCWs.
METHODS
METHODS
In 2018, suspected patients and contacts exposed during a measles outbreak were investigated based on their medical histories and vaccination status. Cases were confirmed by the detection of measles-specific immunoglobulin M or RNA. After the measles outbreak in 2018, measles IgG testing was conducted on a total of 972 HCWs for point-prevalence, including those exposed to the measles. In addition, we have routinely performed measles IgG tests on newly employed HCWs within one week of their hire date since 2019. The measles vaccine was administered to HCWs who tested negative or equivocally negative for IgG antibodies.
RESULTS
RESULTS
An index patient who returned from China with fever and rash was diagnosed with measles at a hospital in Korea. Two additional HCWs were revealed as measles cases: one was vaccinated with the two-dose measles-mumps-rubella (MMR) vaccine, and the other, who was born in 1967, was presumed to have immunity from natural infection in South Korea. All three patients harbored the same D8 genotype. No additional measles cases were identified among the 964 contacts of secondary patients. A total of 2310 HCWs, including those tested during the 2018 outbreak, underwent measles IgG tests. The average age at the time of the test was 32.6 years, and 74.3% were female. The overall seropositivity of measles was 88.9% (95% confidence interval, 87.5-90.1). Although the birth cohorts between 1985 and 1994 were presumed to have received the measles-rubella (MR) catch-up vaccination in 2001, 175 (89.3%) HCWs were born after 1985 among the 195 seronegative cases.
CONCLUSION
CONCLUSIONS
Despite high population immunity, imported measles transmission occurred among HCWs with presumed immunity. This report underscores the importance of understanding the prevalence of measles susceptibility among newly employed HCWs. This is important for policymaking regarding hospital-wide vaccinations to prevent the spread of vaccine-preventable diseases.
Identifiants
pubmed: 37766181
pii: vaccines11091505
doi: 10.3390/vaccines11091505
pmc: PMC10535736
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
MMWR Morb Mortal Wkly Rep. 2018 Oct 26;67(42):1186-1188
pubmed: 30359348
J Infect Dis. 2016 Dec 15;214(12):1980-1986
pubmed: 27923955
PLoS One. 2018 Feb 15;13(2):e0188957
pubmed: 29447169
Commun Dis Intell Q Rep. 2002;26(2):273-8
pubmed: 12206382
Vaccine. 2004 Dec 2;23(3):290-7
pubmed: 15530670
BMC Infect Dis. 2022 May 4;22(1):427
pubmed: 35509007
Nat Rev Microbiol. 2006 Dec;4(12):900-8
pubmed: 17088933
J Korean Med Sci. 2015 Nov;30 Suppl 2:S115-21
pubmed: 26617443
Front Public Health. 2020 Dec 01;8:600196
pubmed: 33335880
Vaccine. 2008 Apr 16;26(17):2111-8
pubmed: 18343536
J Infect Dis. 2011 Jul;204 Suppl 1:S483-90
pubmed: 21666204
Vaccine. 2017 Jul 24;35(33):4126-4132
pubmed: 28669617
Korean J Pediatr. 2012 Dec;55(12):455-61
pubmed: 23300500
MMWR Recomm Rep. 2011 Nov 25;60(RR-7):1-45
pubmed: 22108587
Int J Infect Dis. 2015 Apr;33:12-4
pubmed: 25447718
J Public Health (Oxf). 2014 Sep;36(3):375-81
pubmed: 24099734
BMC Infect Dis. 2019 Jul 5;19(1):582
pubmed: 31277589
J Clin Microbiol. 1992 Nov;30(11):2874-80
pubmed: 1452657
J Med Virol. 1993 Sep;41(1):44-8
pubmed: 8228936
J Infect Dis. 2004 May 1;189 Suppl 1:S27-35
pubmed: 15106086
J Korean Med Sci. 2017 Nov;32(11):1876-1878
pubmed: 28960044
Am J Infect Control. 2014 Aug;42(8):885-7
pubmed: 25087140
Infect Chemother. 2019 Mar;51(1):58-61
pubmed: 30941939
Clin Infect Dis. 2014 May;58(9):1205-10
pubmed: 24585562
Am J Infect Control. 2013 Jul;41(7):661-3
pubmed: 23352075
Euro Surveill. 2018 Jun;23(24):
pubmed: 29921344
MMWR Morb Mortal Wkly Rep. 2019 Dec 06;68(48):1112-1116
pubmed: 31805034
JAMA. 1998 Aug 12;280(6):527-32
pubmed: 9707142
Vaccine. 2020 Jan 10;38(2):107-111
pubmed: 31679860
Hum Vaccin Immunother. 2021 Aug 3;17(8):2517-2521
pubmed: 33689571
Clin Infect Dis. 2012 Aug;55(3):403-5
pubmed: 22543021
Vaccine. 2018 Jun 22;36(27):3888-3889
pubmed: 29223484